top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

3.850 -0.060 (-1.53%)
Delayed Quote Updated: 10:48 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision ↗
Clene (NASDAQ:CLNN) said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for... 
Via MarketBeat
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
From BioMedWire
Via GlobeNewswire
News headline image
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses ↗
Clene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses... 
Via MarketBeat
News headline image
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS ↗
Clene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of... 
Via MarketBeat
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
Landmark Study Shows How Menopause Influences the Symptoms of Multiple Sclerosis
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results at ECTRIMS 2025
Via Investor Brand Network
New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease
Via Investor Brand Network
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model
Via Investor Brand Network
Research Uncovers Possible Way to Repair Myelin in MS Patients
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Late-Stage Momentum in Neuro Pipeline
Via Investor Brand Network
Pioneering Therapy Could Slow the Effects of Aging
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy
Via Investor Brand Network
News headline image
Clene Posts 70% Revenue Drop in Q2 ↗
Via The Motley Fool
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20
Via Investor Brand Network
Parkinson’s-Gut Bacteria Link Suggests Surprisingly Simple Treatment Option
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference
Via Investor Brand Network
New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page